作者：Bo Xiao, et al.
關鍵字：Namomedicine
論文來源：期刊
發表時間：2016年
1. Xiao B.*, Zhang Z, Viennois E, Kang Y, Zhang M, Han MK, Chen J, Merlin D. Combination Therapy for Ulcerative Colitis: Orally Targeted Nanoparticles Prevent Mucosal Damage and Relieve Inflammation. Theranostics 2016;6:2250.（IF = 8.8）
2. Xiao B.*, Xu Z, Viennois E, Zhang Y, Zhang Z, Zhang M, Han MK, Kang Y, Merlin D. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Molecular Therapy 2017;25:1.（Cell子刊，IF = 6.9）
3. Ma L, Xiao B.*, Merlin D. Nanoparticle-mediated co-delivery of chemotherapeutic agent and siRNA for combination cancer therapy. Expert Opinion on Drug Delivery 2017；14:65.（邀請綜述，IF = 5.4）
4. Xiao B.*, Ma P, Viennois E, Merlin D. Urocanic acid-modified chitosan nanoparticles can confer anti-inflammatory effect by delivering CD98 siRNA to macrophages. Colloids and Surfaces B: Biointerfaces 2016;143:186.（IF = 3.9）
5. Xiao B.*, Ma P, Ma L, Chen Q, Si X, Walter L, Merlin D. Effects of tripolyphosphate on cellular uptake and RNA interference efficiency of chitosan-based nanoparticles in Raw 264.7 macrophages. Journal of Colloid and Interface Science 2017;490:520.（IF = 3.7）
6. Si XY, Merlin D, Xiao B*. Recent advances in orally administered cell-specific nanotherapeutics for inflammatory bowel disease. World Journal of Gastroenterology 2016;22:7718.（邀請綜述，IF = 2.7）